Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Inhibition of BET bromodomain proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a biologically aggressive variant of Endometrial Cancer

(2018) Elena Bonazzoli et al.   CLINICAL CANCER RESEARCH

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms

(2016) Xiarong Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ovarian cancer

(2016) Ursula A. Matulonis et al.   Nature Reviews Disease Primers

Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing

(2015) Jung-Yun Lee et al.   BMC CANCER

Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations

(2015) T. Dogruluk et al.   CANCER RESEARCH

Whole–genome characterization of chemoresistant ovarian cancer

(2015) Ann-Marie Patch et al.   NATURE

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data

(2014) F. Favero et al.   ANNALS OF ONCOLOGY

An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

(2014) Maria Giuseppina Baratta et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

(2013) Ali Bashashati et al.   JOURNAL OF PATHOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

(2013) S. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia

(2012) J. R. Brown et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

(2011) Kristin M Nieman et al.   NATURE MEDICINE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Genetic diagnosis by whole exome capture and massively parallel DNA sequencing

(2009) Murim Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutant p53 Gain-of-Function in Cancer

(2009) M. Oren et al.   Cold Spring Harbor Perspectives in Biology

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH